Sanofi (ENXTPA:SAN) received FDA approval for Dupixent as the first and only treatment for allergic fungal rhinosinusitis, expanding its use into a new indication. The company also appointed Belén ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) received FDA approval for Dupixent as the first treatment for allergic fungal rhinosinusitis in both adults and children. The FDA also accepted garetosmab for ...

Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis. Approval in adults and children aged 6 years and older supp ...

Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placebo In the US, there are more than 300,000 adults and adolescents aged 12 years and older ...

Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study Study met the primary and all key secondary ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. The Food and Drug Administration on Friday approved a ...

Dupixent may become the first targeted treatment for bullous pemphigoid in the U.S., pending FDA approval by June 2025. Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has accepted a ...

Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms ...